Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
Site Search
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
Aim is to Provide Cystic Fibrosis Patients Enhanced Access to Medications and Expanded Pharmacy Services
The Cystic Fibrosis Foundation today mourns the passing of legendary sports journalist Frank Deford, whose young daughter Alex lost her fight to CF in 1980, and who served as chair of the Cystic Fibrosis Foundation's Board of Trustees from 1982-1999.
Update: On February 3, 2017, the Cystic Fibrosis Foundation divested its remaining ownership stake in CF Services Inc., a specialty pharmacy. The pharmacy is now fully owned by Walgreens.
Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021.
As a mother of three sons with cystic fibrosis, Mary along with her husband, Harry, was determined to do all she could to find a cure.
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.
The Cystic Fibrosis Foundation mourns the passing of long-standing CF community champion and philanthropic leader who helped to raise more than $500 million toward the CF cause.